Yazan Alkawaleet, MD
Cardiovascular Disease · Wichita, KSNPI 1255781399
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.3%), travel and lodging and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Medtronic at 34.0% of the total. Reporting peaked in 2023 at $3,263 and has fallen 55.4% since, to $1,454 in 2025.
Across 167 payments — averaging $46.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Edwards Lifesciences$3K
- Abiomed$583
- Abbott$386
- E.r. Squibb & Sons, L.L.C.$375
- Novartis$295
- plus $918 from 14 others
What the payments were for
- Travel & lodging$3,54045%
- Food & beverage$4,23454%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 38 | $2,649 |
| Edwards Lifesciences | 35 | $2,590 |
| Abiomed | 8 | $583 |
| Abbott | 3 | $386 |
| E.r. Squibb & Sons, L.L.C. | 18 | $375 |
| Novartis | 18 | $295 |
| Shockwave Medical, Inc | 2 | $170 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $149 |
| Johnson & Johnson | 7 | $118 |
| Pfizer | 7 | $107 |
| Boehringer Ingelheim | 5 | $81 |
| Merck | 4 | $68 |
| Bayer | 2 | $39 |
| Amgen | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $29 |
| Lexicon Pharmaceuticals, Inc. | 1 | $25 |
| Novo Nordisk | 1 | $24 |
| Lantheus Medical Imaging, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,797 in reported general payments places this provider in the 80th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 781 | $621,121 |
| FarxigaDapagliflozin Propanediol | 239 | $166,837 |
| XareltoRivaroxaban | 180 | $145,114 |
| MultaqDronedarone Hcl | 109 | $94,941 |
| EntrestoSacubitril/Valsartan | 48 | $41,302 |
| JardianceEmpagliflozin | 71 | $38,982 |
| Repatha SureclickEvolocumab | 27 | $17,937 |
| Repatha SyringeEvolocumab | 16 | $16,158 |
| Potassium Chloride | 299 | $3,905 |
| Metoprolol Succinate | 451 | $3,588 |
| Nitroglycerin | 198 | $2,960 |
| Flecainide Acetate | 45 | $2,112 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 232 | $1,929 |
| Ranolazine ErRanolazine | 38 | $1,832 |
| Bumetanide | 71 | $1,750 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $107 | $621,121781 claims |
| Johnson & JohnsonXarelto | $118 | $145,114180 claims |
| NovartisEntresto | $295 | $41,30248 claims |
| Boehringer IngelheimJardiance | $81 | $38,98271 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Wichita
- Bassem ChehabWichita$482K
- Joseph GalichiaWichita$177K
- Wassim ShaheenWichita$137K
- Layne ReusserWichita$91K
- Aziz MaksoudWichita$81K
- Hossein AmiraniWichita$18K
- Ahmed MohamedWichita$17K
- Daniel AlvarezWichita$16K
- Freidy EidWichita$13K
- Mohamad FarhatWichita$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.